UK life science competitiveness indicators 2022: measuring what matters most?
The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The indicators did not bring universal […]
The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The indicators did not bring universal […]
Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s potential as an international life sciences leader, […]
A just-published report on the UK’s life sciences sector “ought to ring alarm bells across government,” according to the Association of the British Pharmaceutical Industry […]
With initiatives like The 100,000 Genome Project, the UK has led the world on genomic research. In a bid to maintain that position, the governments […]
AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi, Allergan and Britannia Pharma have been reprimanded for running advertisements that breached the Association of British Pharmaceutical Industry (APBI) code […]
One year ago, a UK-wide vision for the country’s future research landscape promised streamlined processes, and a patient-centred, competitive environment. But how far have we […]
With staff shortages and digital skill gaps being experienced across the spectrum of healthcare, from CROs and pharma to providers, the people-led sector is facing […]
Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind. If the UK creates […]
In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring international uptake of medicines. The publication of […]
Groups representing the biopharma industry have welcomed an increase in health-specific R&D to £5 billion in the UK autumn budget, despite a longer timeline for […]
The pandemic had a negative effect on clinical research across all countries, but the UK seems to be taking longer than others to recover, according […]
Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As […]
How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI […]
The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances […]
The UK’s long-awaited Life Sciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep […]
The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an […]
The Association of the British Pharmaceutical Industry (ABPI) has launched its 2021 Code of Practice to help companies operate to high ethical standards. The ABPI […]
The UK government used the Queen’s Speech to set out its ambition to make the country a leader in life sciences, garnering a warm response […]
It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “life […]
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the […]
There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the […]
Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have […]
In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third […]
In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at […]
The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some degree of stability – but also plenty […]
The trials and tribulations of 2020 have brought the vital role of research, pharma, and biotech into sharp focus. But how has the push to […]
COVID-19 has laid the UK’s health inequalities bare and created an imperative for the NHS to develop a step-change in how it cares for diverse […]
The UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus vaccines to the population, but welcomed other […]
The UK has been leading research into the COVID-19 outbreak, according to the country’s pharma trade body, but there needs to be a strategy to […]
For over 60 years the ABPI Code of Practice has been key to the UK industry’s self-regulation, and now, as pharma is experiencing its most […]
As populations age, multimorbidity becomes an increasingly pertinent issue for healthcare systems. A new action group from the ABPI seeks to bring the NHS, academia […]
The UK government has asked pharma companies to build a six-week stockpile of drugs and find alternative shipping routes to the congested Dover-Calais crossing as […]
Copyright © 2024 | WordPress Theme by MH Themes